Journal
JOURNAL OF UROLOGY
Volume 187, Issue 5, Pages 1876-1881Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.juro.2011.12.058
Keywords
testis; SOX2 protein, human; carcinoma, embryonal; neoplasms, germ cell and embryonal; RNA, small interfering
Categories
Funding
- Ministry of Education, Culture, Sports, Science, and Technology, Japan
- Japanese Society of Laboratory Medicine Fund for the Promotion of Scientific Research
- Takeda Science Foundation
- Princess Takamatsu Cancer Research Fund [4-23603]
- Grants-in-Aid for Scientific Research [21592040] Funding Source: KAKEN
Ask authors/readers for more resources
Purpose: Some nonseminomatous germ cell tumors are resistant to any type of chemotherapy. Control of embryonal carcinoma cells is crucial to manage nonseminomatous germ cell tumors. We established SOX2 targeting therapy in an embryonal carcinoma model. Materials and Methods: SOX2 expression was evaluated in a series of testicular germ cell tumor tissue samples. The antitumor effect of SOX2 knockdown was analyzed in vitro and in vivo using an embryonal carcinoma model. Results: In testicular germ cell tumor tissue SOX2 was expressed in the foci of embryonal carcinoma but negative in seminoma and yolk sac tumors. In an embryonal carcinoma model SOX2-siRNA induced apoptotic cell death in vitro and significant growth suppression in vivo. Conclusions: This study shows the therapeutic potential of SOX2 silencing for embryonal carcinoma. However, further improvements are needed in SOX2-siRNA delivery to the tumor.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available